Last 12 months
Inside the activity.
0 purchase rows · 54 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 10 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 3 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 5 |
| May 2026 | 0 | 12 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 6 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 07, 2026 Filed May 9, 2026 01:16 UTC |
Chopra DaveenCVP, TMTT & Surgical
|
GrantPerformance Rights · Derivative | 9,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005043 · doc4.xml · derivative · entry 5 Chopra Daveen · CIK 0001740963 · CVP, TMTT & Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,675 Underlying: Common Stock · 9,675 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards. Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:16 UTC |
Chopra DaveenCVP, TMTT & Surgical
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 49,100 | $0.00 Strike: $82.76 | $0.00 |
DisclosureSEC source: 0001225208-26-005043 · doc4.xml · derivative · entry 4 Chopra Daveen · CIK 0001740963 · CVP, TMTT & Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,100 Underlying: Common Stock · 49,100 shares Expires 2033-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:16 UTC |
Chopra DaveenCVP, TMTT & Surgical
|
Tax withholdingCommon Stock | 674 | $83.20 | $56,076.80 |
DisclosureSEC source: 0001225208-26-005043 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, TMTT & Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,920 Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:16 UTC |
Chopra DaveenCVP, TMTT & Surgical
|
GrantCommon Stock | 9,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005043 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT & Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,594 F1 · shares: These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:15 UTC |
Bruls AnnetteCVP, EMEACLA
|
GrantPerformance Rights · Derivative | 6,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005042 · doc4.xml · derivative · entry 4 Bruls Annette · CIK 0002032351 · CVP, EMEACLA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,650 Underlying: Common Stock · 6,650 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards. Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:15 UTC |
Bruls AnnetteCVP, EMEACLA
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 33,700 | $0.00 Strike: $82.76 | $0.00 |
DisclosureSEC source: 0001225208-26-005042 · doc4.xml · derivative · entry 3 Bruls Annette · CIK 0002032351 · CVP, EMEACLA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,700 Underlying: Common Stock · 33,700 shares Expires 2033-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:15 UTC |
Bruls AnnetteCVP, EMEACLA
|
GrantCommon Stock | 6,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005042 · doc4.xml · nonDerivative · entry 1 Bruls Annette · CIK 0002032351 · CVP, EMEACLA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,821 F1 · shares: These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2026 Filed May 12, 2026 01:33 UTC |
Markowitz WayneCVP, JAPAC
|
GrantPerformance Rights · Derivative | 5,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005132 · doc4.xml · derivative · entry 6 Markowitz Wayne · CIK 0001991414 · CVP, JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,200 Underlying: Common Stock · 5,200 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards. Read SEC document |
| May 07, 2026 Filed May 12, 2026 01:33 UTC |
Markowitz WayneCVP, JAPAC
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 26,400 | $0.00 Strike: $82.76 | $0.00 |
DisclosureSEC source: 0001225208-26-005132 · doc4.xml · derivative · entry 5 Markowitz Wayne · CIK 0001991414 · CVP, JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2033-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2026 Filed May 12, 2026 01:33 UTC |
Markowitz WayneCVP, JAPAC
|
Tax withholdingCommon Stock | 264 | $83.20 | $21,964.80 |
DisclosureSEC source: 0001225208-26-005132 · doc4.xml · nonDerivative · entry 2 Markowitz Wayne · CIK 0001991414 · CVP, JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,498.8708 Read SEC document |
| May 07, 2026 Filed May 12, 2026 01:33 UTC |
Markowitz WayneCVP, JAPAC
|
GrantCommon Stock | 5,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005132 · doc4.xml · nonDerivative · entry 1 Markowitz Wayne · CIK 0001991414 · CVP, JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,762.8708 F1 · shares: These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2026 Filed May 12, 2026 01:32 UTC |
Zovighian Bernard JDirector · CEO
|
GrantPerformance Rights · Derivative | 43,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005131 · doc4.xml · derivative · entry 10 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,800 Underlying: Common Stock · 43,800 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards. Read SEC document |
| May 07, 2026 Filed May 12, 2026 01:32 UTC |
Zovighian Bernard JDirector · CEO
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 245,300 | $0.00 Strike: $82.76 | $0.00 |
DisclosureSEC source: 0001225208-26-005131 · doc4.xml · derivative · entry 9 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,300 Underlying: Common Stock · 245,300 shares Expires 2033-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 07, 2026 Filed May 12, 2026 01:32 UTC |
Zovighian Bernard JDirector · CEO
|
Tax withholdingCommon Stock | 4,153 | $83.20 | $345,529.60 |
DisclosureSEC source: 0001225208-26-005131 · doc4.xml · nonDerivative · entry 2 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,904.6499 Read SEC document |
| May 07, 2026 Filed May 12, 2026 01:32 UTC |
Zovighian Bernard JDirector · CEO
|
GrantCommon Stock | 43,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005131 · doc4.xml · nonDerivative · entry 1 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,057.6499 F1 · shares: These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 05, 2026 Filed May 5, 2026 23:08 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 13,000 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-26-004969 · doc4.xml · derivative · entry 5 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,000 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2026 Filed May 5, 2026 23:08 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
Tax withholdingCommon Stock | 11,131 | $82.91 | $922,871.21 |
DisclosureSEC source: 0001225208-26-004969 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,948 Read SEC document |
| May 05, 2026 Filed May 5, 2026 23:08 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
Exercise / conversionCommon Stock | 13,000 | $59.26 | $770,337.10 |
DisclosureSEC source: 0001225208-26-004969 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2026 Filed May 5, 2026 23:05 UTC |
Zovighian Bernard JDirector · CEO
|
GiftCommon Stock | 523 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-004968 · doc4.xml · nonDerivative · entry 3 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 12,039.5511 Read SEC document |
| May 05, 2026 Filed May 5, 2026 23:05 UTC |
Zovighian Bernard JDirector · CEO
|
GiftCommon Stock | 523 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-004968 · doc4.xml · nonDerivative · entry 2 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,257.6499 Read SEC document |
| May 04, 2026 Filed May 4, 2026 23:30 UTC |
Lippis Daniel J.CVP, TAVR
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 1,019 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-26-004909 · doc4.xml · derivative · entry 8 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,019 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2026 Filed May 4, 2026 23:30 UTC |
Lippis Daniel J.CVP, TAVR
|
SaleCommon Stock | 1,019 | $83.98 | $85,575.62 |
DisclosureSEC source: 0001225208-26-004909 · doc4.xml · nonDerivative · entry 6 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,681.9103 Read SEC document |
| May 04, 2026 Filed May 4, 2026 23:30 UTC |
Lippis Daniel J.CVP, TAVR
|
Exercise / conversionCommon Stock | 1,019 | $59.26 | $60,382.58 |
DisclosureSEC source: 0001225208-26-004909 · doc4.xml · nonDerivative · entry 5 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,700.9103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2026 Filed May 4, 2026 23:30 UTC |
Lippis Daniel J.CVP, TAVR
|
Tax withholdingCommon Stock | 252 | $83.98 | $21,162.96 |
DisclosureSEC source: 0001225208-26-004909 · doc4.xml · nonDerivative · entry 4 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,681.9103 Read SEC document |
| May 03, 2026 Filed May 4, 2026 23:29 UTC |
Chopra DaveenCVP, TMTT & Surgical
|
Tax withholdingCommon Stock | 282 | $83.98 | $23,682.36 |
DisclosureSEC source: 0001225208-26-004908 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT & Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,919 Read SEC document |
| May 03, 2026 Filed May 4, 2026 23:29 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Tax withholdingCommon Stock | 469 | $83.98 | $39,386.62 |
DisclosureSEC source: 0001225208-26-004907 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,797.2532 Read SEC document |
| May 03, 2026 Filed May 5, 2026 23:08 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
Tax withholdingCommon Stock | 620 | $83.98 | $52,067.60 |
DisclosureSEC source: 0001225208-26-004969 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,079 Read SEC document |
| May 03, 2026 Filed May 5, 2026 23:05 UTC |
Zovighian Bernard JDirector · CEO
|
Tax withholdingCommon Stock | 515 | $83.98 | $43,249.70 |
DisclosureSEC source: 0001225208-26-004968 · doc4.xml · nonDerivative · entry 1 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,780.6499 Read SEC document |
| May 01, 2026 Filed May 4, 2026 23:30 UTC |
Lippis Daniel J.CVP, TAVR
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 1,019 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-26-004909 · doc4.xml · derivative · entry 7 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,019 Underlying: Common Stock · 1,019 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2026 Filed May 4, 2026 23:30 UTC |
Lippis Daniel J.CVP, TAVR
|
SaleCommon Stock | 1,000 | $82.99 | $82,988.90 |
DisclosureSEC source: 0001225208-26-004909 · doc4.xml · nonDerivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,933.9103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $82.540 to $83.490. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2026 Filed May 4, 2026 23:30 UTC |
Lippis Daniel J.CVP, TAVR
|
SaleCommon Stock | 19 | $83.99 | $1,595.77 |
DisclosureSEC source: 0001225208-26-004909 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,933.9103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $83.980 to $84.095. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2026 Filed May 4, 2026 23:30 UTC |
Lippis Daniel J.CVP, TAVR
|
Exercise / conversionCommon Stock | 1,019 | $59.26 | $60,382.58 |
DisclosureSEC source: 0001225208-26-004909 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,952.9103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. Read SEC document |
| April 09, 2026 Filed Apr 9, 2026 23:34 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 13,000 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-26-004476 · doc4.xml · derivative · entry 5 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 09, 2026 Filed Apr 9, 2026 23:34 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
SaleCommon Stock | 8,324 | $79.79 | $664,143.66 |
DisclosureSEC source: 0001225208-26-004476 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,699 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $79.210 to $80.200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 09, 2026 Filed Apr 9, 2026 23:34 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
SaleCommon Stock | 4,676 | $80.50 | $376,400.70 |
DisclosureSEC source: 0001225208-26-004476 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,023 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $80.225 to $80.750. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 09, 2026 Filed Apr 9, 2026 23:34 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
Exercise / conversionCommon Stock | 13,000 | $59.26 | $770,337.10 |
DisclosureSEC source: 0001225208-26-004476 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025. Read SEC document |
| April 06, 2026 Filed Apr 7, 2026 00:42 UTC |
Lippis Daniel J.CVP, TAVR
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 1,019 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-26-004422 · doc4.xml · derivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,038 Underlying: Common Stock · 1,019 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 06, 2026 Filed Apr 7, 2026 00:42 UTC |
Lippis Daniel J.CVP, TAVR
|
SaleCommon Stock | 1,019 | $80.98 | $82,522.70 |
DisclosureSEC source: 0001225208-26-004422 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,933.9103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $80.64 to $81.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 06, 2026 Filed Apr 7, 2026 00:42 UTC |
Lippis Daniel J.CVP, TAVR
|
Exercise / conversionCommon Stock | 1,019 | $59.26 | $60,382.58 |
DisclosureSEC source: 0001225208-26-004422 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,952.9103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. Read SEC document |
| April 02, 2026 Filed Apr 2, 2026 21:13 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 22,680 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-26-004249 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,680 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 02, 2026 Filed Apr 2, 2026 21:13 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
SaleCommon Stock | 18,004 | $80.05 | $1,441,209.40 |
DisclosureSEC source: 0001225208-26-004249 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,266.2532 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $79.490 to $80.435. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2026 Filed Apr 2, 2026 21:13 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
SaleCommon Stock | 4,676 | $80.59 | $376,845.85 |
DisclosureSEC source: 0001225208-26-004249 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,270.2532 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $80.510 to $80.660. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 02, 2026 Filed Apr 2, 2026 21:13 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Exercise / conversionCommon Stock | 22,680 | $59.26 | $1,343,941.96 |
DisclosureSEC source: 0001225208-26-004249 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,946.2532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. Read SEC document |
| March 11, 2026 Filed Mar 11, 2026 21:15 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 13,000 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-26-003539 · doc4.xml · derivative · entry 5 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 13,000 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2026 Filed Mar 11, 2026 21:15 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
SaleCommon Stock | 7,901 | $85.21 | $673,227.62 |
DisclosureSEC source: 0001225208-26-003539 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,699 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $84.865 to $85.790. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 11, 2026 Filed Mar 11, 2026 21:15 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
SaleCommon Stock | 5,099 | $84.46 | $430,668.17 |
DisclosureSEC source: 0001225208-26-003539 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,600 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $83.865 to $84.860. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 11, 2026 Filed Mar 11, 2026 21:15 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
Exercise / conversionCommon Stock | 13,000 | $59.26 | $770,337.10 |
DisclosureSEC source: 0001225208-26-003539 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025. Read SEC document |
| March 11, 2026 Filed Mar 11, 2026 21:10 UTC |
Lippis Daniel J.CVP, TAVR
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 1,019 | $0.00 Strike: $59.26 | $0.00 |
DisclosureSEC source: 0001225208-26-003538 · doc4.xml · derivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,057 Underlying: Common Stock · 1,019 shares Expires 2026-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2026 Filed Mar 11, 2026 21:10 UTC |
Lippis Daniel J.CVP, TAVR
|
SaleCommon Stock | 1,019 | $85.38 | $87,004.46 |
DisclosureSEC source: 0001225208-26-003538 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,933.9103 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $85.16 to $85.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide,uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 11, 2026 Filed Mar 11, 2026 21:10 UTC |
Lippis Daniel J.CVP, TAVR
|
Exercise / conversionCommon Stock | 1,019 | $59.26 | $60,382.58 |
DisclosureSEC source: 0001225208-26-003538 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,952.9103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.